文献速递其他结缔组织病

托法替布单药维持治疗幼年皮肌炎:一例病例报告

Tofacitinib monotherapy as maintenance treatment in juvenile dermatomyositis: a case report.
PubMed 文献 · RMD Open · 2025-05-21

本文报告一例幼年皮肌炎患儿在既往治疗失败后,采用托法替布单药治疗获得持续缓解。作者指出托法替布目前仅限用于难治性病例,但该结果提示其可能更早整合入治疗流程。

要点

  • 幼年皮肌炎管理困难,尤其重症或难治性病例,治疗选择证据有限。
  • Janus激酶抑制剂包括托法替布已成为有前景的替代选择,但儿科人群证据仍 scarce。
  • 本例患儿经托法替布单药治疗获得持续缓解,提示或可更早整合入治疗流程。

核心结论

  • 一例幼年皮肌炎患儿在既往治疗失败后,采用托法替布单药治疗获得持续缓解。
  • 作者认为托法替布目前仅限用于难治性病例,但该结果提示其可能更早整合入治疗流程。

研究设计与样本

  • 病例报告,报告一例幼年皮肌炎患儿的诊治经过。

主要发现

  • 该患儿在既往治疗失败后,接受托法替布单药治疗并获得持续缓解。

临床怎么用

  • 作者指出托法替布目前仅限用于难治性病例,但该结果提示其可能更早整合入治疗流程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Juvenile dermatomyositis (JDM) is a multisystem autoimmune disease associated with considerable morbidity and mortality, having a significant impact on patient health. Early diagnosis and appropriate treatment play a key role in optimising outcomes. JDM management remains challenging, particularly in severe or refractory cases, due to the limited evidence regarding therapeutic options. Given these challenges, Janus kinase inhibitors, including tofacitinib, have emerged as promising alternatives, yet evidence in paediatric populations is still scarce. We present the case of a child with JDM who achieved sustained remission with tofacitinib monotherapy following the failure of previous therapies. While its use is currently restricted to refractory cases, these findings suggest its potential for earlier integration into treatment algorithms. This work aims to provide valuable insights to guide therapeutic strategies in JDM.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Argüelles Balas D, Barral Mena E, Martín Díaz MÁ, et al. Tofacitinib monotherapy as maintenance treatment in juvenile dermatomyositis: a case report. RMD Open. 2025. PMID: 40404182. doi:10.1136/rmdopen-2025-005651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。